Frankfurt - Delayed Quote EUR

Dicot Pharma AB (KN0.F)

Compare
0.0282 +0.0047 (+20.00%)
As of 9:17:53 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Ms. Elin Trampe Chief Executive Officer 1.79M -- 1980
Dr. Jarl Wikberg Ph.D. Founder & Chief Scientific Officer 67.75k -- --
Mr. Bjorn Petersson Chief Financial Officer -- -- 1961
Dr. Mats Silvander Ph.D. Chief Technical Officer -- -- --
Ms. Charlotta Gauffin Chief Scientific Officer -- -- 1971
Ms. Julie Silber Director of Investor Relations -- -- --
Ms. Gabriela Urquilla Director of Communications -- -- --
Mr. Hakan Wickholm Chief Business Officer -- -- 1959

Dicot Pharma AB

S:t Olofsgatan 11A
Uppsala, 753 21
Sweden
46 7 25 02 10 10 https://www.dicotpharma.com
Sector: 
Healthcare
Full Time Employees: 
3

Description

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

Corporate Governance

Dicot Pharma AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers